A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics

Journal of Pediatric Endocrinology and Metabolism

Volumn 24, Issue 9-10, 2011, Pages 619-626

  Nwosu, Benjamin U ^a   Meltzer, Bruce ^a   Maranda, Louise ^a   Ciccarelli, Carol ^a   Reynolds, Daniel ^a   Curtis, Laura ^a   King, Jean ^a   Frazier, Jean A ^a   Lee, Mary M ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Antipsychotics; Obesity; Psychosis; Vitamin D

Indexed keywords

AMANTADINE; ANTIRETROVIRUS AGENT; ARIPIPRAZOLE; CERULENIN; DOPAMINE RECEPTOR; ERGOCALCIFEROL; GLUCOCORTICOID; HORMONE PRECURSOR; METFORMIN; MOLINDONE; OLANZAPINE; QUETIAPINE; RIFAMPICIN; RISPERIDONE; SIBUTRAMINE; TAMOXIFEN; TETRAHYDROLIPSTATIN; TOPIRAMATE; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ARTICLE; BODY COMPOSITION; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; FEASIBILITY STUDY; GASTROINTESTINAL TOXICITY; GLUCOSE METABOLISM; HUMAN; HYPOPHAGIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; MENTAL DISEASE; NAUSEA; NONHUMAN; OBESITY; OSTEOMALACIA; PILOT STUDY; RECEPTOR AFFINITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; STOMACH DISCOMFORT; VITAMIN D DEFICIENCY; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; OBESITY; PILOT PROJECTS; PSYCHOTIC DISORDERS; VITAMIN D; VITAMINS; WEIGHT GAIN;

EID: 80054076722     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/JPEM.2011.300     Document Type: Article

References (88)

1. Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2002;59:1-6.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. (Pubitemid 41345943)
3. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, et al. Randomized controlled trial of the effect on quality of life of second-vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87. (Pubitemid 44498387)
4. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97. (Pubitemid 351418005)
5. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006;16(Suppl 3):S149-55. (Pubitemid 44175821)
6. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12.
7. Basu R, Brar JS, Chengappa KN, John V, Parepally H, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004;6:314-8. (Pubitemid 39077092)
8. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9. (Pubitemid 36618288)
9. Diabetes and obesity: time to act. Brussels: Federation TID, 2004.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 2002;287:356-9. (Pubitemid 34251969)
11. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 2003;26:3153-9. (Pubitemid 37339513)
12. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, et al. Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am J Psychiatry 2008;165:1420-31.
13. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 2009;302:1765-73.
14. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48:60-70.
15. Makimura H. Obesity and antipsychotic drug use. MGH Neuroendocrine Clinical Center Bulletin 2008;14:4-5.
16. Seeman P, Tallerico T, Ko F. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: implications for human positron emission tomography. Synapse 2003;49:209-15. (Pubitemid 36927961)
17. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 2011;29:127-48, viii.
18. Henderson DC. Weight gain with atypical antipsychotics: evidence and insights. J Clin Psychiatry 2007;68(Suppl 12):18-26. (Pubitemid 350021619)
19. Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 2002;22:6742-6. (Pubitemid 35386430)
20. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995;374:542-6.
21. Stahl SM. Neuropharmacology of obesity: my receptors made me eat it. J Clin Psychiatry 1998;59:447-8. (Pubitemid 28447196)
22. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-3.
23. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57(Suppl 11):4-11.
24. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kühn M, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999;156:312-4. (Pubitemid 29077125)
25. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-9.
26. Hagg S, Soderberg S, Ahren B, Olsson T, Mjorndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 2001;62:843-8. (Pubitemid 33131169)
27. Prolo P, Wong ML, Licinio J. Leptin. Int J Biochem Cell Biol 1998;30:1285-90. (Pubitemid 29004416)
28. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64:598-604. (Pubitemid 36618291)
29. Auwerx J, Staels B. Leptin. Lancet 1998;351:737-42. (Pubitemid 28106955)
30. Herran A, Garcia-Unzueta MT, Amado JA, de La Maza MT, Alvarez C, et al. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 2001;179:59-62.
31. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, et al. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005;30:184-91. (Pubitemid 40024412)
32. McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001;62(Suppl 23):23-9. (Pubitemid 32952691)
33. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007;32:289-97. (Pubitemid 46106936)
34. Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, et al. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 2008;28:494-9.
35. Schwenkreis P, Assion HJ. Atypical antipsychotics and diabetes mellitus. World J Biol Psychiatry 2004;5:73-82. (Pubitemid 44121716)
36. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-43. (Pubitemid 29407221)
37. Vickers SP, Benwell KR, Porter RH, Bickerdike MJ, Kennett GA, et al. Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol 2000;130:1305-14. (Pubitemid 30488594)
38. Sibley SD. Plasma vitamin D predicted weight loss in obese individuals. In: The Endocrine Society's 91st Annual Meeting, June 10-13, 2009, Washington, DC, 2009.
39. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162:954-62. (Pubitemid 40676209)
40. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159:655-7. (Pubitemid 34274950)
41. Shin L, Breeze J, Noyes N, Frazier JA. Metformin for weight control in pediatric patients on atypical antipsychotic medications. J Child Adolesc Psychopharmacol 2009;19:275-9.
42. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163:2072-9. (Pubitemid 46114226)
43. Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006;51:192-6.
44. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006;186:572-8.
45. Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, et al. Orlistat in clozapine-or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:706-11. (Pubitemid 351838679)
46. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 2005;162:1744-6. (Pubitemid 41318248)
47. Canitano R. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005;27:228-32. (Pubitemid 40312035)
48. Knox JM. A study of weight reducing diets in psychiatric in-patients. Br J Psychiatry 1980;136:287-9. (Pubitemid 10081829)
49. Eckel RH. Clinical practice. Nonsurgical management of obesity in adults. N Engl J Med 2008;358:1941-50.
50. Shin L, Bregman H, Breeze JL, Noyes N, Frazier JA. Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol 2009;19:275-9.
51. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008;122:398-417.
52. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, et al. The 2011 report on dietary reference intakes for calcium and vitamin d from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
53. Tsoukas CD, Provvedini DM, Manolagas SC. 1, 25-Dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 1984;224:1438-40.
54. Pritchard RS, Baron JA, Gerhardsson de Verdier M. Dietary calcium, vitamin D, and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol Biomarkers Prev 1996;5:897-900. (Pubitemid 26382983)
55. Rasanen P, Hakko H, Jarvelin MR. Prenatal and perinatal risk factors for psychiatric diseases of early onset. Results are different if seasons are categorised differently. Br Med J 1999;318:1622-3. (Pubitemid 29267783)
56. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500-3. (Pubitemid 33055701)
57. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980;209:823-5. (Pubitemid 10017495)
58. Kadowaki S, Norman AW. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest 1984;73:759-66. (Pubitemid 14156858)
59. von Hurst PR, Stonehouse W, Matthys C, Conlon C, Kruger MC, et al. Study protocol - metabolic syndrome, vitamin D and bone status in South Asian women living in Auckland, New Zealand: a randomised, placebo-controlled, double-blind vitamin D intervention. BMC Public Health 2008;8:267.
60. Lucas JA, Bolland MJ, Grey AB, Ames RW, Mason BH, et al. Determinants of vitamin D status in older women living in a subtropical climate. Osteoporos Int 2005;16:1641-8. (Pubitemid 41790869)
61. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 1995;38:1239-45.
62. Isaia G, Giorgino R, Adami S. High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 2001;24:1496.
63. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, et al. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract 1995;27:181-8.
64. Kumar S, Davies M, Zakaria Y, Mawer EB, Gordon C, et al. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 1994;70:440-3. (Pubitemid 24196871)
65. Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 2003;57:258-61. (Pubitemid 36700706)
66. Gedik O, Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia 1986;29:142-5. (Pubitemid 16137021)
67. Alemzadeha R, Kichlerb J, Babara G, Calhouna M. Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism 2008;57:183-91.
68. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007;30:980-6. (Pubitemid 46556596)
69. Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, et al. The relationship between obesity and serum 1, 25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 2004;89:1196-9. (Pubitemid 38368412)
70. Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH. Low circulating vitamin D in obesity. Calcif Tissue Int 1988;43:199-201.
71. Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, et al. Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 1985;76:370-3. (Pubitemid 15243466)
72. Zamboni G, Soffiati M, Giavarina D, Tato L. Mineral metabolism in obese children. Acta Paediatr Scand 1988;77:741-6.
73. Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005;115:177-86. (Pubitemid 40385519)
74. Holick MF. Stay tuned to PXR: an orphan actor that may not be D-structive only to bone. J Clin Invest 2005;115:32-4. (Pubitemid 40385502)
75. Karaaslan Y, Haznedaroglu S, Ozturk M. Osteomalacia associated with carbamazepine/valproate. Ann Pharmacother 2000;34:264-5.
76. Cardinal RN, Gregory CA. Osteomalacia and vitamin D deficiency in a psychiatric rehabilitation unit: case report and survey. BMC Res Notes 2009;2:82.
77. Rehman HU. Persistently raised alkaline phosphatase in a woman with osteomalacia. Br Med J 2009;338:b1874.
78. Hey H, Stokholm KH, Lund B, Lund B, Sorensen OH. Vitamin D deficiency in obese patients and changes in circulating vitamin D metabolites following jejunoileal bypass. Int J Obes 1982;6:473-9. (Pubitemid 12000152)
79. Zemel MB, Sun X. Calcitriol and energy metabolism. Nutr Rev 2008;66:S139-46.
80. Rohe B, Safford SE, Nemere I, Farach-Carson MC. Identification and characterization of 1, 25D3-membrane-associated rapid response, steroid (1, 25D3-MARRS)-binding protein in rat IEC-6 cells. Steroids 2005;70:458-63. (Pubitemid 40616044)
81. Zemel MB. Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. J Am Coll Nutr 2002;21:146S-51S. (Pubitemid 38622950)
82. Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1alpha, 25-Dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic action. FASEB J 2001;15:2751-3.
83. Martinez de Morentin PB, Varela L, Ferno J, Nogueiras R, Dieguez C, et al. Hypothalamic lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010;1801:350-61.
84. Lane MD, Wolfgang M, Cha SH, Dai Y. Regulation of food intake and energy expenditure by hypothalamic malonyl-CoA. Int J Obes (Lond) 2008;32(Suppl 4):S49-54.
85. Lopez M, Lelliott CJ, Tovar S, Kimber W, Gallego R, et al. Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 2006;55:1327-36. (Pubitemid 44195371)
86. Gao S, Lane MD. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci USA 2003;100:5628-33. (Pubitemid 36576859)
87. Shimokawa T, Kumar MV, Lane MD. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proc Natl Acad Sci USA 2002;99:66-71. (Pubitemid 34060317)
88. APA diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000.